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Anti-androgen therapyAbstract Purpose: It is clear that triple-negative breast cancer (TNBC) tumors are heterogeneous
group, but clinically important sub-sets have begun to emerge. We investigate the immunohisto-
chemical expression of androgen receptor (AR) among those hormonal insensitive groups which
have only the option of chemotherapy. Exploiting this knowledge for therapy has been challenging.
Patients & methods: Seventy seven patients with TNBC subtype, treated from January 2009 until
February 2011 were evaluated for AR expression where AR-positive expression group (P10%
nuclear stained cells) was conducted to receive anti-androgen therapy post adjuvant chemotherapy
(Bicalutamide ‘‘Casodex’’) 50 mg, once daily with or without meals at the same time each day, to
date. AR expression was correlated with other prognostic factors and survival (disease free survival
(DFS) and overall survival (OS)). Cox proportional hazard model was used to assess variables in
the multivariate analysis.
Results: The median age in the present study was 35.6 year (19–63 years). The median follow-up
period was 24 months (3–60 months). AR-positive expression in the present study was (21n77)
27.27% correlated with clinical outcomes, for recurrent event (n= 4, 19.05%), (P= 0.000, HR
12.750, Cl 95% 3.668–44.318) and for death event, no body died in AR positive expression group
(P= 0.000, HR 0.644, Cl 95% 0.533–0.779). Improved survival with AR-positive expression group
for 2-year and 3-year DFS was 85% and 78% respectively with (P=<0.001, Cl 95% 39.17–
51.39) and for OS at 2-year and 3-year was 100% (P= 0.0005). In univariate and multivariate anal-
ysis, AR positive expression with anti-androgen therapy in TNBC patients in our present study had
retained their independent prognostic value for DFS (P= 0.0006, HR 4.659, Cl 95% 1.553–
13.977). Bicalutamide was well-tolerated therapy with no grade 3/4 treatment-related adverse events.
Conclusions: Bicalumide is well tolerated in AR positive TNBC subtype patients and could offer an
alternative to cytotoxic chemotherapy in those patients with better OS and DFS.
ª 2015 The Authors. Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Androgen receptor (AR) positivity has been detected in
approximately half of all breast carcinoma cases.1,2 High
(AR) expression in breast cancer has been correlated with a
low risk of recurrence and death.1
AR has been shown to have prognostic implications in
breast carcinoma, and higher AR expression levels have been
associated with older age at diagnosis, higher expression of
ER or PR, lower nuclear grades, and smaller tumor size.2,3
Triple-negative breast cancers (TNBC) were recently
divided into further subtypes including a subtype with high
AR expression.4
Previous studies looking at AR expression in TNBC have
demonstrated that AR negativity has been associated with a
shorter disease-free interval and overall survival than AR-
positive TN cancer. These studies suggest that AR expression
could be a useful prognostic marker in TN tumors.4
AR is expressed in 60–70% of breast tumors independent of
estrogen status, and in 20–32% of TNBC patients. Estrogen
and Progesterone and the gene HER-2, these are the three
big markers and/or targets in breast cancer. Evidence pre-
sented at the AACR Annual Meeting 2013 adds a fourth:
androgen receptors.5
2. Patients and methods
This Retrospective study was conducted in Clinical Oncology
Department and Histopathological Department, Tanta
University 2009 until February 2011. The study included 77
consecutively treated patients with TNBC. The established
clinical and histo-morphological factors of all patients were
assessed. The steroid hormones status including (ER, PR,
Her.2, AR and KI-67) was evaluated by immunohistochem-
istry (IHC).
The aim of this study focused on predictive and prognostic
value of AR expression as a hormonal marker in TNBC
patients.
2.1. Immunohistochemistry for ER, PR, HER-2, AR and KI-67
For immune-staining, 3–5 mm sections were deparafﬁnized
with 40 min incubation at 60_C and subsequent immersion
in xylene, and were rehydrated in solutions of decreasing etha-
nol. Then specimens were incubated in 0.3% H2O2 for 30 min
to inhibit activation of endogenous peroxidases. Slides were
then washed with phosphate-buffered saline (PBS) and heated
in an 830-W microwave oven for at least 15 min in 10 mmol/l
sodium citrate buffer (pH 6.0) for antigen retrieval. Sections
were incubated with primary antibodies against [mouse mono-
clonal, androgen receptors (ab9474 1:500 dilution), rabbit
monoclonal Estrogen receptor (ab37438 1:25 dilution), rabbit
monoclonal Progesterone receptor (ab2765 1:25 dilution),
rabbit monoclonal HER-2 receptor (ab134182 1:100 dilution)
and Rabbit polyclonal KI-67 (ab15580 1:100 dilution) over-
night at 4_C. For the negative control, the primary antibody
was replaced with phosphate buffered saline (PBS). Rabbit
anti-mouse horseradish peroxidase-conjugated secondary anti-
body was added followed by incubation for 40 min at room
temperature. The color was developed using diaminobenzidine
(DAB) as a chromogen. Slides were extensively washed withPBS after each step. Finally they were counter-stained with
Mayer’s hematoxylin.
The immunostaining results for ER, PR & AR were
assessed semiquantitatively and reported as positive if more
than 10% of cells have nuclear immunostaining in a tumor.
Tumor cells were considered positive for HER2 protein over-
expression when more than 10% of the cells showed complete
moderate or strong membrane staining. Ki 67 immunostaining
was considered positive if there were nuclear staining in more
than 10% of the tumor cells.6
2.1.1. Study design
Seventy seven TNBC patients were classiﬁed into two
sub-groups according to AR-expression proﬁle, where AR-
positive expression group 21/77 (27.27%) designated to receive
anti-androgen therapy post adjuvant traditional chemotherapy,
Bicalutamid 50 mg once daily with or without meals at the same
time each day still received to date.
At the time of primary treatment, none of the patients had
any evidence of distant metastases. After the completion of the
primary treatment, our TNBC patients underwent regular
follow-up examinations at our department for DFS and OS
as regards AR expression proﬁle. All the procedures were in
accordance with the ethical standards of our faculty’s Ethical
committee.
2.1.2. Statistical analysis
Statistical presentation and analysis of the present study were
conducted, using Number and percentage for qualitative and
tested by chi-square test. We used Kaplan–Meier and Cox
regression for survival analysis by SPSS for windows version
18.0 software package (SPSS Inc., Chicago, 11) and
P value =<0.05%. Overall survival (OS) deﬁned the length
of time from the date of diagnosis and the patients still alive
either free or not. Disease-free survival (DFS) expresses the
period after curative treatment (disease eliminated) when no
disease can be detected.
3. Results
At the time of the primary treatment, none of the patients had
any evidence of distant metastases.
The tumor’s, patient’s and treatment’s characteristics in 77
TNBC patients are presented in Table 1, the median age of the
patients was 35.6 years (range, 19–63). Age >35 years was
50.65%, premenopausal at the presentation was 52.63%,
patients had grade III tumors 32.47%, tumor size larger than
2 cm was 27.27%, and patients had invasive ducal carcinoma
(IDC) (92.21%). At least one axillary lymph node was positive
in 57.14% of patients, and positive mitotic index was 67.53%.
In twenty one patients (21/77) 27.27% were positive for AR
expression in TNBC patients in the present study. Positive
AR immunostaining was inversely correlated with large tumor
size (P= 0.001), nodal status (P= 0.007), high grade
(p= 0.000) and higher Ki67 (p= 0.08). Positive AR expres-
sion was associated with age less than 35 years (42.86%),
female patients (100%), premenopausal status (42.86%) and
no patients had stage III at presentation. For AR negatively
expressed tumors in TNBC patients in the present study
51.79% was associated with age <35, 3 male patients
(5.36%), premenopausal status (56.36%). Stage III at
Table 1 Tumor’s and treatment’s characteristics in 77 TNBC
patients.
Patients characteristics N %
Age <35. 38 49.35
>35. 39 50.65
Sex Female 74 96.10
Male 3 3.90
PS 0 54 70.13
1 21 27.27
2 2 2.60
Body mass index <25 47 61.04
>25 30 38.96
Menopause status Pre 40 52.63
Post 36 47.37
Tumor stage Stage I 11 14.29
Stage II 43 55.84
Stage III 23 29.87
T T1 19 24.68
T2 37 48.05
T3 20 25.97
T4 1 1.30
N N0 33 42.86
N1 32 41.56
N2 12 15.58
Pathological subtypes Ductal 71 92.21
Lobular 1 1.30
Other 5 6.49
Grade Grade I 7 9.09
Grade II 45 58.44
Grade III 25 32.47
CA15.3 Positive 20 25.97
Negative 57 74.03
Chemotherapy regimens A/C 32 41.56
T/A 45 58.44
AR exp Positive 21 27.27
Negative 56 72.73
Ki67 Positive 52 67.53
Negative 25 32.47
Brain No 58 75.32
Yes 19 24.68
Bone No 71 92.21
Yes 6 7.79
Lung No 57 74.03
Yes 20 25.97
Liver No 71 92.21
Yes 6 7.79
Local No 67 87.01
Yes 10 12.99
Table 2 Clinical outcomes in 77 TNBC patients.
Clinical outcomes N %
DFS event 0 31 40.26
1 46 59.74
Outcome Alive 59 76.62
Died 18 23.38
Androgen in Breast Cancer 133presentation was 41.07%, 35.7% presented as T3, N2 in
21.43%, 92.86% presented with IDC histology subtype, GIII
in 42.86%, high CA15.3 in 32.14% of patients and 73.21%
presented with high KI-67 more than 14%. All patients
underwent the radical local treatment, all patients of this study
received anthracycline-based chemotherapy regimens A/C
(Adriamycin and cyclophosphamide), T/A (Taxol and
adriamycin) Table 1
3.1. Follow-up
Local and distant recurrences were 59.74% (n= 46) of
patients and 23.38% (n= 18) patients were died in the whole
studied population of TNBC (Table 2).The median follow-up was 24 months (range, 3–60)
months. Ten (12.99%) patients experienced local recurrence,
45 (58.44%) patients experienced distant recurrence and 18
(23.38%) patients were died, in the entire study (Table 3).
The risk of relapse (local spread) in AR-positive group
(n= 1, 4.76%) versus (N= 9, 16.07%) in AR-negative group
with p value = 0.15, for distal spread (n= 3, 14.28%) versus
(n= 42, 75.00%) for AR-Positive and AR-negative groups
respectively, (p= 0.000). AR-expression was positively associ-
ated with clinical outcomes for recurrent event (n= 4, 19.05%
versus n= 42, 75%), AR-Positive and negative groups respec-
tively (P= 0.000, HR = 12.750, 95 Cl% 3.668, 44.318), for
death event nobody died in AR positive group in comparison
with (n= 18, 32.9%) for AR-negative group (P= 0.000, HR
0.644, Cl 95% 0.533–0.739) Table 4.
3.2. Survival plots
The median overall-survival (OS) of the entire group was
46.58 months with 5-Year OS 63% (Fig. 1). Median
disease-free-survival (DFS) was 22.00 months with 5-year
DFS 18% and in the entire group we found a pattern of
maximum recurrence and death rates in the ﬁrst 3 years
following the diagnosis and a clear decline after that
(Fig. 2).
The median OS, was 35 months for AR-ve group with no
death in AR positive group received anti-androgen therapy;
2-year OS was 100% versus 74%, 3-year OS was 100% ver-
sus 42% and 5-year OS was 100% versus 42% for AR-
positive and AR-negative groups respectively (P= 0.0005)
‘‘Fig. 3’’.
The median DFS was 45.26 months versus 14.00 in AR-
positive with anti-androgen therapy and AR-negative groups
respectively with (P= 0.000). 2-Year DFS was 85% versus
28%, 3-year DFS was 78% versus 20% and 78% versus 5%
at 5-year DFS (p=<0.001), for AR+ positive and AR-
negative groups respectively ‘‘Fig. 4’’.
3.3. Univariate and multivariate survival analysis
In the univariate analysis (Table 5), AR expression was posi-
tively associated with nodal status, grade, Ki67 and CA 15.3
with signiﬁcant impact on DFS (P= 0.001, 0.043, <0.001,
0.003). In the multivariate analysis (Table 6) for DFS, only
AR expression group which received anti-androgen therapy,
tumor grade and ki-67 proliferation index retained their
in-dependent prognostic and predictive values in TNBC
patients (P= 0006, HR 4.659, CI 95% 1.553–13.977): for
AR expression, (P= 0.000, HR 4.105, CI 95% 2.065–8.159),
for tumor grade, and (P= 0.000, HR 0.281, CI 95%
0.119–0.665) for Ki-67.
Table 3 Correlation of different prognostic factors with AR expression (AR+ve versus AR-ve groups).
Prognostic factors AR therapy Chi-square
Positive Negative Total X2 P-value
N % N % N %
Age <35 9 42.86 29 51.79 38 49.35 0.488 0.485
>35 12 57.14 27 48.21 39 50.65
Sex Female 21 100.00 53 94.64 74 96.10 1.956 0.162
Male 0 0.00 3 5.36 3 3.90
PS 0 17 80.95 37 66.07 54 70.13 2.513 0.285
1 4 19.05 17 30.36 21 27.27
2 0 0.00 2 3.57 2 2.60
Body mass index <25 9 42.86 38 67.86 47 61.04 3.949 0.047
>25 12 57.14 18 32.14 30 38.96
Menopause status Pre 9 42.86 31 56.36 40 52.63 1.113 0.291
Post 12 57.14 24 43.64 36 47.37
Stage Stage I 4 19.05 7 12.50 11 14.29 18.103 0.000
Stage II 17 80.95 26 46.43 43 55.84
Stage III 0 0.00 23 41.07 23 29.87
T T1 7 33.33 12 21.43 19 24.68 16.147 0.001
T2 14 66.67 23 41.07 37 48.05
T3 0 0.00 20 35.71 20 25.97
T4 0 0.00 1 1.79 1 1.30
N N0 13 61.90 20 35.71 33 42.86 9.996 0.007
N1 8 38.10 24 42.86 32 41.56
N2 0 0.00 12 21.43 12 15.58
Path subtypes Ductal 19 90.48 52 92.86 71 92.21 2.750 0.253
Lobular 1 4.76 0 0.00 1 1.30
Other 1 4.76 4 7.14 5 6.49
Grade Grade I 5 23.81 2 3.57 7 9.09 16.177 0.000
Grade II 15 71.43 30 53.57 45 58.44
Grade III 1 4.76 24 42.86 25 32.47
CA15.3 Positive 2 9.52 18 32.14 20 25.97 4.671 0.031
Negative 19 90.48 38 67.86 57 74.03
Chemotherapy regimens A/C 8 38.9 24 42.86 32 41.56 2.278 0.320
T/A 13 61.90 32 57.14 45 58.44
AR exp Positive 21 100.00 0 0.00 21 27.27 90.237 0.000
Negative 0 0.00 56 100.00 56 72.73
Ki67 Positive 11 52.38 41 73.21 52 67.53 2.923 0.087
Negative 10 47.62 15 26.79 25 32.47
Brain No 20 95.24 38 67.86 58 75.32 7.676 0.006
Yes 1 4.76 18 32.14 19 24.68
Bone No 21 100.00 50 89.29 71 92.21 4.008 0.045
Yes 0 0.00 6 10.71 6 7.79
Lung No 20 95.24 37 66.07 57 74.03 8.425 0.004
Yes 1 4.76 19 33.93 20 25.97
Liver No 20 95.24 51 91.07 71 92.21 0.405 0.525
Yes 1 4.76 5 8.93 6 7.79
Local No 20 95.24 47 83.93 67 87.01 2.049 0.152
Yes 1 4.76 9 16.07 10 12.99
Table 4 Relation of AR-expression and clinical outcomes.
Clinical outcomes AR therapy Chi-square Odd ratio
Positive Negative Total
N % N % N % X2 P-value Odd L U
DFS event 0 17 80.95 14 25.00 31 40.26 20.372 0.000 12.750 3.668 44.318
1 4 19.05 42 75.00 46 59.74
Out come Alive 21 100.00 38 67.86 59 76.62 13.414 0.000 0.644 0.533 0.779
Died 0 0.00 18 32.14 18 23.38
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Figure 1 OS in the entire study group Median = 46.58
SE = 2.64.
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Figure 2 DFS in the entire study group Median = 22.00
SE = 4.39.
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Figure 3 OS in both study groups according to AR-expression
(AR+ve and AR-ve).
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Figure 4 DFS in both study groups according to AR-expression
(AR+ve and AR-ve).
Table 5 Univariate analysis of the entire group for our study (77 patients) TNBC of different prognostic factors as regard DFS.
Prognostic factors 2y. 3y. Median SE CI 95% Log rank test P-value
Age <35 0.396 0.346 22.000 6.600 (9.06–34.94) 0.140 0.709
>35 0.487 0.411 24.000 7.360 (9.58–38.42)
Menopause Pre 0.367 0.275 18.000 6.400 (5.46–30.54) 2.290 0.131
Post 0.538 0.500 29.000 6.580 (16.11–41.89)
AR exp Positive 0.847 0.786 45.260 3.100 (39.17–51.35) 21.710 <0.001*
Negative 0.276 0.201 14.000 1.360 (11.34–16.66)
AR therapy Positive 0.847 0.786 45.260 3.100 (39.17–51.35) 21.710 <0.001*
Negative 0.276 0.201 14.000 1.360 (11.34–16.66)
Chemotherapy regimens A/C 0.450 0.360 24.000 10.560 (3.29–44.71) 0.620 0.733
T/A 0.444 0.377 22.000 4.340 (13.50–30.50)
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Table 6 Multivariate analysis of the entire group for signiﬁcant prognostic factors as regard DFS.
Prognostic factors B SE Wald Sig. Exp (B) 95.0% CI for Exp (B)
Lower Upper
AR exp 1.539 0.561 7.535 0.006 4.659 1.553 13.977
T 0.085 0.205 0.173 0.678 0.918 0.615 1.372
N 0.005 0.226 0.000 0.983 1.005 0.645 1.566
Grade 1.412 0.351 16.228 0.000 4.105 2.065 8.159
Ki67 1.270 0.440 8.333 0.004 0.281 0.119 0.665
CA15.3 0.018 0.340 0.003 0.957 0.982 0.504 1.912
136 F. Zakaria et al.3.4. Toxicity proﬁle for anti-androgen therapy
As regarded Bicalutamide toxicity proﬁle, no patient presented
with grade 3/4 toxicity, only 6n21 patients, 28.57% presented
with breast tenderness of fullness and hot ﬂushes (n= 2), Feeling
sick (nausea) (n= 3), weight gain (n= 1) and all of them con-Figure 5a A case of invasive ductal carcinoma grade III showing
negative immunohistochemical stain for estrogen receptor [Strep-
tavidin biotin · 400].
Figure 5b The same case of invasive ductal carcinoma grade III
showing negative immunohistochemical stain for progesterone
receptor [Streptavidin biotin · 400].trolled, Bicalutamid still received as hormonal therapy to date
among AR-positively expressed subtype in the present study.
3.5. Immunohistochemical results
See Figs. 5a–5d and Figs. 6–8.Figure 5d The same case of invasive ductal carcinoma grade III
showing positive immunohistochemical stain for androgen recep-
tors in more than 10% of the tumor cells [Streptavidin
biotin · 400].
Figure 5c The same case of invasive ductal carcinoma grade III
showing negative immunohistochemical stain for HER-2 receptors
[Streptavidin biotin · 400].
Figure 6 A case of invasive breast carcinoma grade I showing
positive immunohistochemical stain for androgen receptors in
more than 10% of the tumor cells [Streptavidin biotin · 400].
Figure 7 A case of invasive breast carcinoma grade II showing
positive immunohistochemical stain for androgen receptors in
more than 10% of the tumor cells [Streptavidin biotin · 100].
Figure 8 A case of invasive breast carcinoma grade III showing
positive immunohistochemical stain for androgen receptors in
more than 10% of tumor cells [Streptavidin biotin · 400].
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To date, studies on patients with TNBC have been limited
mostly by the small sample sizes and short follow-up times.
Our present retrospective study was conducted in 77 TNBC
patients treated in the routine clinical practice with the median
follow-up time of almost 24 months.
In the study, TNBC patients had relatively large tumors at
presentation (more than 2 cm in 27.27% of patients), pre-
menopausal (52.63%), predominant type of tumor was inva-
sive ductal carcinoma (92.21%), poorly differentiated
(32.47%), positive ki-67 > 14% (67.53%), almost more than
half of patients (57.14%) had positive axillary lymph nodes
and twenty-one patients (27.27%) were positive for AR expres-
sion at presentation (Table 1). Also, in some previous reports
triple-negative tumors were presented in premenopausal young
women with poorer clinical outcomes similar to our results,
median DFS was 4 years among women who were diagnosed
between age 31–40 years compared with 8 years among women
diagnosed at age 60 or older (7). TNBC tumors were described
as relatively large (>2 cm) with high rate of node positivity7–15
similar to our results. Other investigators found that character-
istically TNBC exhibits an invasive ductal histology and a high
histologic grade, presented with high mitotic index.16–18 In the
population based Carolina Breast Cancer Study (CBCS), basal
like breast cancers (deﬁned by triple negative status plus
EGFR and/or cytokeratin 5 positivity) were virtually all of
ductal or mixed histology 90% and of high grade (84%),
whereas TNBC is identiﬁed tumor subtype characterized by
aggressive behavior and poor prognosis where the majority
of triple-negative cases were of high grade and of large tumor
size19–24 similar to our results. TNBC cases are associated with
higher expression of ki-67 than non-TNBC and so ki-67 can be
used for further classiﬁcation of TNBC into two subtypes with
different response and prognosis.25–27 Garay et.al.28 stated that
AR was expressed in 10–35% of TNBC patients and also, sta-
ted by Richer5 (5. Traditionally, chemotherapy has been the
mainstay of systemic treatment for TNBC, TNBC is highly
responsive to primary anthracycline and anthracycline/taxane
protocols, however, a high risk of relapse remains29–31 similar
to our study).
AR expression was signiﬁcantly related to older age at
diagnosis, smaller tumor size, well differentiated tumors, lower
proliferative index, lack of lymph node metastasis and of
ductal type.8,17,32–38
TNBC patients with androgen negative have a higher pro-
portion of positive lymph nodes,3 higher level of pre-operative
CA15.3, larger tumor size, higher grade.19,39,40 It has been doc-
umented that AR expression is related to positive prognostic
factors.8,33,38,41
Correlation between histopathologic grade and the expres-
sion of all sex hormone receptors in breast tumors revealed
that as tumor grade progressed from 1 to 3 AR-expression
decreased from 95% to 76% in ductal carcinoma in situ
(DCIS) and 88–47% in invasive carcinoma. In the same anal-
ysis, ER expression decreased from 100% to 8% in DCIS and
to 9.5% in invasive carcinoma with increasing tumor grade.28
In our study as a whole, the median follow-up was
24 months (range, 3–60) where 12.99% of patients experienced
local recurrences, 58.44% of patients experienced distal recur-
rence and 23.38% of patients died. Two-year OS was 82% and
138 F. Zakaria et al.67% for 3-year OS, as regards DFS in the whole study 2-year
DFS was 46% and 31% for 3-year DFS. Pattern of metastasis
was 25.97%, 24.68%, 7.79% and 7.79% for lung, brain, liver
and bone respectively. Other investigators agreed with us
where TNBC was reported to have higher rate of recurrences
and decreased overall survival.4,8,27,37,42–44
Albergaria et al.10 suggested that there was a signiﬁcant
association of tumor size, histologic grade and lymph node sta-
tus to high scores of NPI (Nottingham prognostic index) in
TNBC. In terms of survival there is a sharp decrease in sur-
vival during the ﬁrst 3–5 years after diagnosis but distant after
that time is much less common.11,23,31,45–48 In a study pub-
lished by Dent et al.48 the median time to death was 3.5 years
for TNBC compared to 5.7 years for patients with other can-
cers. In fact, as we can infer by the survival functions, TNBC
experienced a severe decrease in their outcomes before
48 months as seen in their overall survival curves.10,49 The
prognosis of women with TNBC is signiﬁcantly poor, com-
pared to women with other subtypes of breast cancer, and
the underlying differences in recurrence and patient mortality
rates may be explained in part by different routes of metastatic
spread. The current theory points out the suggestion that
TNBC metastasizes to axillary bones less frequently than the
non-triple negative subset of breast tumors, favoring a
hematogenous spread16,23,45 similar to our results.
Mohamed et al.19 showed that TNBC is identiﬁed tumor
subtypes characterized by aggressive behavior and poor prog-
nosis. TN phenotype was associated with high microvessel
invasion. The majority of TN cases were of high grade and
of large size with biologically heterogeneous group of tumors
where expression of basal markers with vascular invasion
was 26%, preferable metastatic dissemination sites were vis-
ceral like brain, lung and liver and less to the bone (40% lung,
30% brain, 20% liver and 10% bone) in agreement with our
results, with 3-year OS with complete pathological remission
94% dropped to 68% in patients with less than complete
pathological remission after primary chemotherapy.11,31,44,47
In the present study, Androgen receptor-positive expression
TNBC tumors which received anti-androgen therapy with tol-
erable toxicities, showed favorable clinical outcomes in com-
parison with negatively AR expressed tumors, with 4.76%
local spread and 14.28% distal spread. For recurrent event
19.05% and for death event nobody died in AR-positively
expressed group of TNBC patients. The median DFS was
45.26 months versus 14.00 months in AR-positive and AR-
negative groups respectively, 2-year DFS was 85% versus
28%, 3-year DFS was 78% versus 20% for AR-positive and
negative groups, respectively. As regards 2-year OS was
100% versus 74% and 3-year OS was 100% versus 42% for
AR positive versus AR-negative groups respectively.
AR-dependent cell cycle progression is a critical regulator
of the G1-S transition in prostatic carcinoma, and a similar
role may be envisaged in breast cancer.41 The sensitivity and
speciﬁcity and likelihood ratio of AR for therapeutic response
were higher relatively to other markers, individually and also
in combination. AR expression showed inverse correlation
with EGFR, and loss of EGFR would lead to suppression of
cell growth and consequently would result in better therapeutic
response.41 Because AR ligands can have opposing and para-
doxical effects in various breast cancer cell lines expressing
AR, applying AR-targeted therapies for breast cancer treat-
ment has been challenging.28,32,37,49Thike et al.40 suggest that loss of AR in TNBC augurs a
worse prognosis and predicts early recurrence in TN and basal
like breast cancer. DFS was signiﬁcant in AR-positive TNBC
with trend to improve OS was noted within 5 years of diagno-
sis, and also, other investigators28,31,33,50–53 stated a signiﬁcant
correlation between AR expression and DFS and OS, similar
to our results in AR expression group which received anti-
androgen targeted therapy (Bicalutamide, (casodex) where
the prognostic marker give a sufﬁcient level of evidence in this
subgroup).4,28,54–62
In the present study, the univariate analysis and the multi-
variate analysis retained the signiﬁcant prognostic value of AR
expression with positive impact on DFS and OS in TNBC
patients. This is in agreement with many researchers.5,28,31,51
In conclusions, it is apparent that AR inhibition can stabi-
lize disease in TNBC patients. Bicalumide is well tolerated in
AR positive patients and could offer an alternative to cyto-
toxic chemotherapy in those patients. TNBC needs for a para-
digm shift in personalized treatment than one size ﬁts all.
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